AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10982926 — intervention group
Group type: COMPARATOR
Intervention: simplified standard edgewise technique
Number of subjects: 90
Study 10982926 — intervention group
Group type: COMPARATOR
Intervention: edgewise straight wire system
Number of subjects: 90
Study 8971373 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (10 micrograms/kg/day)
Number of subjects: 403
Study 8971373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 1294745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 182
Study 1294745 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (analgesic and antiinflammatory doses)
Number of subjects: 182
Study 4007361 — intervention group
Group type: EXPERIMENTAL
Intervention: M-mode echocardiography
Number of subjects: 36
Study 30322875 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened twice or three times
Number of subjects: 31867
Study 30322875 — intervention group
Group type: COMPARATOR
Intervention: Screened once
Number of subjects: 31867
Study 30322875 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 31867
Study 30322875 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened three times
Number of subjects: 31867
Study 28130574 — intervention group
Group type: EXPERIMENTAL
Intervention: PDUS-guided core-needle biopsy (CNCB)
Number of subjects: 372
Study 28130574 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical biopsy (OSB)
Number of subjects: 372
Study 26192721 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF followed by physiotherapy
Number of subjects: 60
Study 26192721 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 60
Study 23220919 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg INH twice weekly for 6 months
Number of subjects: 0
Study 23220919 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 21612950 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-task rehearsal (PTr)
Number of subjects: 20
Study 21612950 — intervention group
Group type: COMPARATOR
Intervention: Full-task rehearsal (FTr)
Number of subjects: 20
Study 19531640 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet and aerobic exercise (1 h/day at 65% of maximal oxygen uptake)
Number of subjects: 16
Study 19531640 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric diet and aerobic exercise (1 h/day at 65% of maximal oxygen uptake)
Number of subjects: 16
Study 16783518 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Associations Task
Number of subjects: 39
Study 16783518 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal word-generation and simple association tasks
Number of subjects: 39
Study 15504190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixyrazine 10 mg
Number of subjects: 197
Study 15504190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 11526982 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (10 mg capsule)
Number of subjects: 25
Study 11526982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9760006 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg twice daily
Number of subjects: 45
Study 9760006 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg twice daily plus 125 mg aspirin
Number of subjects: 45
Study 9760006 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 125 mg aspirin
Number of subjects: 45
Study 7919892 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonographic examinations (EUS)
Number of subjects: 22
Study 7919892 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal encapsulated Doxorubicin (20 mg/m2 intravenously every 3 weeks)
Number of subjects: 22
Study 2455155 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (MET), 200 mg slow release (SR) q.d.
Number of subjects: 20
Study 2455155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF), 20 mg SR b.i.d.
Number of subjects: 20
Study 2455155 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (MET)
Number of subjects: 20
Study 31628477 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performed before breakfast
Number of subjects: 2
Study 31628477 — intervention group
Group type: COMPARATOR
Intervention: Exercise performed after breakfast
Number of subjects: 2
Study 31628477 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training performed before carbohydrate intake
Number of subjects: 2
Study 31628477 — intervention group
Group type: COMPARATOR
Intervention: Exercise training performed after carbohydrate intake
Number of subjects: 2
Study 29939254 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 36
Study 28679410 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment at CV8, CV12, LI4 and ST36, 30-min treatments twice a week for 8 weeks
Number of subjects: 96
Study 28679410 — intervention group
Group type: COMPARATOR
Intervention: Sham moxibustion at non-acupoints, 30-min treatments twice a week for 8 weeks
Number of subjects: 96
Study 28679410 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (no moxibustion treatment)
Number of subjects: 96
Study 26235788 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective strabismus surgery (n = 63)
Number of subjects: 130
Study 26235788 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring without surgery (n = 57)
Number of subjects: 130
Study 22486205 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 20
Study 21635753 — intervention group
Group type: EXPERIMENTAL
Intervention: Staircase recruitment manoeuvres (SRM) with decremental PEEP titration and targeted plateau pressure < 30 cm H2O
Number of subjects: 20
Study 21635753 — intervention group
Group type: COMPARATOR
Intervention: Control ventilation strategies (ARDSnet)
Number of subjects: 20
Study 19783515 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered cherry stalk (2.0 grams per person)
Number of subjects: 13
Study 17050481 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive mobile phone users
Number of subjects: 21
Study 17050481 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 21
Study 12757064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (2 capsules of 0.5 g ginger powder each, taken 1 hour before the procedure)
Number of subjects: 80
Study 12757064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study 10702769 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times/day)
Number of subjects: 24
Study 10702769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10096413 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt word reading tasks
Number of subjects: 10
Study 10096413 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt nonword reading tasks
Number of subjects: 10
Study 7901254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 358
Study 7901254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin followed by aspirin plus warfarin
Number of subjects: 358
Study 2449725 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral incision
Number of subjects: 37
Study 2449725 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection
Number of subjects: 37
Study 29940417 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban as uterine relaxant
Number of subjects: 818
Study 29940417 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol as uterine relaxant
Number of subjects: 818
Study 26598955 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected HPV testing kit
Number of subjects: 818
Study 26598955 — intervention group
Group type: COMPARATOR
Intervention: Reminder invitation for Pap testing
Number of subjects: 818
Study 26598955 — intervention group
Group type: COMPARATOR
Intervention: Standard of care opportunistic screening
Number of subjects: 818
Study 24056065 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related rehabilitation programme following a comprehensive functional capacity evaluation (FCE MR)
Number of subjects: 222
Study 24056065 — intervention group
Group type: COMPARATOR
Intervention: Conventional multidisciplinary rehabilitation (C)
Number of subjects: 222
Study 21930514 — intervention group
Group type: EXPERIMENTAL
Intervention: In-shoe foot orthoses
Number of subjects: 40
Study 21930514 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 40
Study 20963310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy (MS)
Number of subjects: 18
Study 20963310 — intervention group
Group type: COMPARATOR
Intervention: Conventional Midsternotomy (CMS)
Number of subjects: 18
Study 19076083 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors (ACE-Is) introduced 3-16 days after MI
Number of subjects: 0
Study 19076083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16550960 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 14572753 — intervention group
Group type: EXPERIMENTAL
Intervention: Permixon (160 mg bid for three months)
Number of subjects: 29
Study 14572753 — intervention group
Group type: EXPERIMENTAL
Intervention: Permixon
Number of subjects: 29
Study 14572753 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment for 3 weeks before surgery)
Number of subjects: 29
Study 10962896 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal colectomy for obstructive left side colonic tumours
Number of subjects: 0
Study 10962896 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision for middle and lower third rectal cancer
Number of subjects: 0
Study 10962896 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivisceral resections for the treatment of advanced colorectal tumours
Number of subjects: 0
Study 9380919 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of propofol administered i.v. immediately after fetal extraction
Number of subjects: 60
Study 9380919 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (equal volume to propofol)
Number of subjects: 60
Study 9380919 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-up antiemetic drug (dehydro-benzoperidol)
Number of subjects: 60
Study 8411145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.4 g long‐chain n‐3 fatty acids/day) for 4 weeks
Number of subjects: 20
Study 8411145 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 20
Study 3964152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 23
Study 3964152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31629656 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus goserelin (10.8 mg subcutaneous injection on the first day of irradiation and 3 months later)
Number of subjects: 743
Study 31629656 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 743
Study 26905082 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait plate insole with shoes
Number of subjects: 17
Study 26905082 — intervention group
Group type: COMPARATOR
Intervention: Shoes only
Number of subjects: 17
Study 25347023 — intervention group
Group type: EXPERIMENTAL
Intervention: Prequit smoking-specific experiential avoidance (EA)
Number of subjects: 40
Study 25347023 — intervention group
Group type: EXPERIMENTAL
Intervention: Prequit smoking-specific EA
Number of subjects: 40
Study 23883408 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive low-glucose suspend (PLGS) system active
Number of subjects: 19
Study 23883408 — intervention group
Group type: COMPARATOR
Intervention: Control (PLGS system inactive)
Number of subjects: 19
Study 21977566 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal birth after caesarean section (VBAC)
Number of subjects: 357
Study 21977566 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of first stage of labour
Number of subjects: 357
Study 21977566 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of second stage of labour
Number of subjects: 357
Study 21977566 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without previous caesarean section)
Number of subjects: 357
Study 21977566 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications of VBAC
Number of subjects: 357
Study 19387560 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum for rotation physicians within the CHIR-Net
Number of subjects: 0
Study 16954475 — intervention group
Group type: EXPERIMENTAL
Intervention: LHA intervention group
Number of subjects: 851
Study 16954475 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 851
Study 15312156 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg
Number of subjects: 246
Study 15312156 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 40-80 mg
Number of subjects: 246
Study 11745199 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2) over 24 hours with cisplatin (75 mg/m2) on a 21‐day cycle
Number of subjects: 68
Study 11745199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2) with gemcitabine (1 g/m2) on Days 1, 8, and 15 on a 28‐day cycle
Number of subjects: 68
Study 11745199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2) with docetaxel (75 mg/m2) on a 21‐day cycle
Number of subjects: 68
Study 11745199 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (225 mg/m2) over 3 hours with carboplatin (area under the curve, 6)
Number of subjects: 68
Study 11745199 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 68
Study 11745199 — intervention group
Group type: COMPARATOR
Intervention: Comparison with patients with PS of 0-1
Number of subjects: 68
Study 9023301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 38
Study 9023301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9023301 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN
Number of subjects: 38
Study 8323380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified, but involves treatment for rheumatoid arthritis with a focus on radiological progression.
Number of subjects: 153
Study 8323380 — intervention group
Group type: COMPARATOR
Intervention: Control not specified, but implies a comparison group in the trial.
Number of subjects: 153
Study 3701668 — intervention group
Group type: EXPERIMENTAL
Intervention: Enuresis wire mesh
Number of subjects: 7
Study 3701668 — intervention group
Group type: COMPARATOR
Intervention: No enuresis wire mesh (control)
Number of subjects: 7
Study 31241204 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 517
Study 31241204 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment to PA
Number of subjects: 517
Study 31241204 — intervention group
Group type: EXPERIMENTAL
Intervention: Model prediction
Number of subjects: 517
Study 31241204 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support and options for PA
Number of subjects: 517
Study 28040448 — intervention group
Group type: EXPERIMENTAL
Intervention: Belladonna and opium rectal suppositories (16.2/60 mg) administered rectally immediately after surgery and every 8 hours for a total of 3 doses.
Number of subjects: 90
Study 28040448 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories administered rectally immediately after surgery and every 8 hours for a total of 3 doses.
Number of subjects: 90
Study 28040448 — intervention group
Group type: EXPERIMENTAL
Intervention: Belladonna and opium rectal suppositories
Number of subjects: 90
Study 28040448 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 90
Study 25270958 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (0.4 mg/kg twice weekly for 8 doses) plus systemic corticosteroids (2.0 mg/kg/day)
Number of subjects: 39
Study 24154773 — intervention group
Group type: EXPERIMENTAL
Intervention: CO₂ insufflation
Number of subjects: 205
Study 24154773 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 205
Study 21285990 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol (DAiS)
Number of subjects: 270
Study 21285990 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone, Aspirin, and deferred addition of Diethylstilbestrol (DAdS)
Number of subjects: 270
Study 21285990 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (before adding Diethylstilbestrol)
Number of subjects: 270
Study 20183665 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439
Study 20183665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 439
Study 20183665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Fluoxetine and CBT
Number of subjects: 439
Study 20183665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 16395727 — intervention group
Group type: COMPARATOR
Intervention: Granulocytapheresis (5 sessions at one session/week over 5 consecutive weeks)
Number of subjects: 14
Study 16395727 — intervention group
Group type: COMPARATOR
Intervention: Granulocytapheresis (for subgroup with duration of BD >= 5 years)
Number of subjects: 14
Study 16395727 — intervention group
Group type: COMPARATOR
Intervention: Granulocytapheresis (for subgroup with duration of BD < 5 years)
Number of subjects: 14
Study 14707831 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide
Number of subjects: 20
Study 14707831 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 11938807 — intervention group
Group type: EXPERIMENTAL
Intervention: QRBCAD medication (Group B)
Number of subjects: 58
Study 11938807 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy without QRBCAD (Group A)
Number of subjects: 58
Study 8704697 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral stem cell transplantation
Number of subjects: 71
Study 8704697 — intervention group
Group type: COMPARATOR
Intervention: Autologous BMT
Number of subjects: 71
Study 8704697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PC pre-chemotherapy
Number of subjects: 71
Study 1513973 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 269
Study 1513973 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 269
Study 6432084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergostin (DE‐145) 2 mg intravenous administration
Number of subjects: 12
Study 6432084 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 30791889 — intervention group
Group type: COMPARATOR
Intervention: Arm A: Stupp protocol (EBRT 60 Gy + 2 cm margin with concomitant temozolomide (TMZ) and 6 months of TMZ maintenance)
Number of subjects: 220
Study 30791889 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: Stupp protocol with additional simultaneous integrated boost of IMRT of 72Gy/2.4Gy delivered on MR spectroscopic imaging metabolic volumes of CHO/NAA > 2 and contrast-enhancing lesions or resection cavity
Number of subjects: 220
Study 29246729 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 119
Study 29246729 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 119
Study 27116647 — intervention group
Group type: COMPARATOR
Intervention: Mental work + rest (MW + R)
Number of subjects: 38
Study 27116647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental work + exercise (MW + E)
Number of subjects: 38
Study 25169846 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin plus neuraminidase inhibitors
Number of subjects: 63
Study 25169846 — intervention group
Group type: COMPARATOR
Intervention: Neuraminidase inhibitors (control group)
Number of subjects: 63
Study 22915298 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-12 supplementation (1 mg i.m. single dose then 500 μg/d orally for 3 months)
Number of subjects: 132
Study 22915298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 20428914 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative resection of colon cancer via minilaparotomy utilizing specific instruments (North‐bridge retractor system)
Number of subjects: 167
Study 20428914 — intervention group
Group type: COMPARATOR
Intervention: Curative resection of colon cancer via minilaparotomy without utilizing specific instruments
Number of subjects: 167
Study 18048435 — intervention group
Group type: COMPARATOR
Intervention: Placebo (LHTL1 group)
Number of subjects: 40
Study 18048435 — intervention group
Group type: EXPERIMENTAL
Intervention: G lucidum 10 capsules/day (LHTL2 group)
Number of subjects: 40
Study 18048435 — intervention group
Group type: EXPERIMENTAL
Intervention: G lucidum 20 capsules/day (LHTL3 group)
Number of subjects: 40
Study 16037127 — intervention group
Group type: EXPERIMENTAL
Intervention: Water drink (7.5 ml/kg body wt)
Number of subjects: 9
Study 16037127 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (0.9%)
Number of subjects: 9
Study 11966935 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of n-6 polyunsaturated fatty acids
Number of subjects: 0
Study 11966935 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 0
Study 11966935 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of n-3 polyunsaturated fatty acids
Number of subjects: 0
Study 10573494 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus lovastatin or simvastatin (statin group, n = 23)
Number of subjects: 43
Study 10573494 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (diet group, n = 20)
Number of subjects: 43
Study 8918492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU (700 mg/m2/d), FA (300 mg/m2/d), and L-OHP (25 mg/m2/d) administered daily for 4 days every 14 days
Number of subjects: 50
Study 8918492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU dose intensity > 1,400 mg/m2/wk over four courses
Number of subjects: 50
Study 8918492 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50